MedTrace Logo

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis

NCT00777868 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2012-06-22

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and effectiveness of two concentrations of IDP-108 in treating patients with onychomycosis

Conditions

  • Onychomycosis

Interventions

DRUG

Low Strength IDP-108

Topical application once a day for 9 months

DRUG

High Strength IDP-108

Topical application once a day for 9 months

DRUG

High Strength IDP-108 under occlusion

Topical application once a day for 9 months

DRUG

Vehicle

Topical application once a day for 9 months

Sponsors & Collaborators

  • Dow Pharmaceutical Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00777868 on ClinicalTrials.gov